Literature DB >> 7537118

Role of B7-1 in mediating an immune response to myeloid leukemia cells.

U A Matulonis1, C Dosiou, C Lamont, G J Freeman, P Mauch, L M Nadler, J D Griffin.   

Abstract

A costimulatory signal from B7-1 (CD80) to its counter-receptor CD28 is required for T-cell activation. Many tumors, including most human leukemias, lack expression of B7-1, and this has been suggested to contribute to the failure of immune recognition of these diseases. A murine leukemia model system was developed to assess the potential role of B7-1 in the induction immunity to leukemia cells. The nonleukemic 32Dc13 myeloid cell line was transformed by transfection of the BCR/ABL gene, generating a subline (32Dp210/clone 26) that was leukemic and rapidly lethal to syngeneic, immunocompetent C3H/HeJ mice or T-cell-deficient nude mice. B7-1-modified leukemic cells remained lethal in nude mice, but caused only a transient, nonlethal leukemia in C3H/HeJ mice. After a single exposure to live, nonirradiated B7-1-modified leukemic cells, C3H/HeJ mice developed protective immunity against subsequent challenge with B7-1(-) leukemic cells. Further, hyperimmunization with B7-1(+) leukemic cells prolonged the survival of mice previously injected with a lethal number of B7-1(-) leukemic cells. These results indicate that myeloid leukemic cells may be attractive candidates for B7-1 gene transfer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537118

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Enhancement of cALL immunogenicity by co-culture with a CD154 expressing 293 cell line.

Authors:  A J Lee; C Haworth; R M Hutchinson; R Patel; R Carter; R F James
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Bcr/Abl expression stimulates integrin function in hematopoietic cell lines.

Authors:  G Bazzoni; N Carlesso; J D Griffin; M E Hemler
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

3.  Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells.

Authors:  A Krämer; S Hörner; A Willer; S Fruehauf; A Hochhaus; M Hallek; R Hehlmann
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

4.  Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.

Authors:  Raphaël F Rousseau; Ettore Biagi; Aurélie Dutour; Eric S Yvon; Michael P Brown; Tiffany Lin; Zhuyong Mei; Bambi Grilley; Edwina Popek; Helen E Heslop; Adrian P Gee; Robert A Krance; Uday Popat; George Carrum; Judith F Margolin; Malcolm K Brenner
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

5.  Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

Authors:  Jeffrey J Molldrem; Peter P Lee; Shreya Kant; Eric Wieder; Weidong Jiang; Sijie Lu; Changqing Wang; Mark M Davis
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

6.  Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

Authors:  J L Schultze; A A Cardoso; G J Freeman; M J Seamon; J Daley; G S Pinkus; J G Gribben; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

Review 7.  Immunological weapons against acute myeloid leukaemia.

Authors:  Joanna Galea-Lauri
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

8.  In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex-vivo generation of CTL for immunotherapy.

Authors:  J K Orleans-Lindsay; A Deru; J I O Craig; H G Prentice; M W Lowdell
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

9.  Defective expression and modulation of B7-2/CD86 on B cells in B cell chronic lymphocytic leukemia.

Authors:  Zhen-sheng Dai; Qin-fen Chen; Hong-zhou Lu; Yi Xie
Journal:  Int J Hematol       Date:  2009-05-09       Impact factor: 2.490

Review 10.  The role of the immune system in anti-tumour responses. Potential for drug therapy.

Authors:  S Dermime; J Barrett; C Gambacorti-Passerini
Journal:  Drugs Aging       Date:  1995-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.